Harbour BioMed and Insilico Medicine Collaborate on AI-Driven Antibody Discovery

Harbour BioMed and Insilico Medicine have announced a strategic collaboration to advance AI-driven antibody discovery and development, announced in a press release. This partnership aims to leverage Harbour BioMed's expertise in antibody development and Insilico's AI capabilities to create innovative therapeutic antibodies.

The collaboration will integrate Harbour BioMed's technology platform and proprietary dataset with Insilico's AI-driven drug discovery platforms. This joint effort focuses on developing next-generation AI-powered antibody applications and early-stage drug discovery programs targeting novel antibodies. The goal is to address unmet medical needs in fields such as immunology, oncology, and neuroscience.

Harbour BioMed's proprietary Harbour Mice® platform is central to this collaboration, enabling the generation of fully human monoclonal antibodies. Insilico Medicine, known for its AI platform that enhances drug discovery efficiency, will contribute its expertise in AI-driven drug development to the partnership. Together, the companies aim to streamline antibody discovery and enhance candidate selection, ultimately bringing innovative therapies to patients more efficiently.